1st Apr 2015 10:11
LONDON (Alliance News) - Deltex Medical Group PLC said Wednesday that has won a new dedicated trainer account in the US, taking its total accounts in the region to eight.
The account is with what Deltex calls a "major level 1 trauma centre", following a clinical evaluation of its CardioQ oesophageal Doppler monitoring product between August and October last year. Monthly usage is expected to start at 50 probes, and the approvals required to expand this usage across all types of major surgery and critical care are in place, Deltex said.
"This creates further substantial progress towards delivering our strategy of building a profitable network of influential major hospitals adopting our products as standards of care. This network will form a strong platform for future national roll-out of ODM in the key US market," said Chief Executive Ewan Phillips in a statement.
The company makes oesophageal Doppler monitoring technology. The monitoring systems are used to measure blood flow during surgery by generating a low-frequency ultrasound signal and utilising the Doppler effect. The Doppler effect is the change in frequency of a wave for an observer moving relative to its source, such as the way in which the noise of a siren changes when it passes by.
The company sends dedicated trainers into hospitals to help train physicians in using its technology.
It had won its seventh dedicated trainer account in January, after winning previous accounts in June and January of last year.
Still, shares in Deltex are trading down 5.7% at 4.13 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Deltex Medical